Skip to main content
. 2011 Apr 18;156(2):816–831. doi: 10.1104/pp.111.176222

Figure 8.

Figure 8.

Schematic representation of the chloroplastic MEP pathway and likely interactions with the cytosolic processes. Enzymatic steps expected to be most susceptible to darkness are indicated by black arrows. The steps inhibited in darkness are denoted by dark gray circled crosses, while the known control point of fosmidomycin inhibition, DXP reductoisomerase (Kuzuyama et al., 1998), is denoted by a light gray circled cross. Additional steps presumably inhibited by fosmidomycin are shown by light gray circled question marks. Abbreviations are as follows: RuBP, ribulose-1,5-bisphosphate; 3-PGA, 3-phosphoglycerate; 2-PGA, 2-phosphoglycerate; 1,3-BPG,1,3-bisphosphoglycerate; GAP, glyceraldehyde 3-phosphate; DHAP, dihydroxyacetone phosphate; PEP, phosphoenolpyruvate; PYR, pyruvate; DXP, 1-deoxy-d-xylulose-5-phosphate; MEP, 2-C-methyl-d-erythritol-4-phosphate; CDP-ME, 4-(cytidine-5-diphospho)-2-C-methyl-d-erythritol; CDP-MEP, 2-phospho-4-(cytidine-5-diphospho)-2-C-methyl-d-erythritol; ME-cDP, 2-C-methyl-d-erythritol 2,4-cyclo-diphosphate; HMBDP, 4-hydroxy-3-methyl-2-(E)-butenyl-diphosphate; IDP, isopentenyl diphosphate; DMADP, dimethylallyldiphosphate; DXS, DXP synthase; DXR, DXP reductoisomerase; MCT, CDP-methyl-d-erythritol synthase; CMK, CDP-methyl-d-erythritol kinase; MDS, methyl-d-erythritol-CDP synthase; HDS, HMBDP synthase; HDR, HMBDP reductase; IDI, IDP isomerase; IspS, isoprene synthase; PK, pyruvate kinase.